NR2E3 and cancer: The de novo biosynthesis of deoxycytidine triphosphate (dCTP), deoxyadenosine triphosphate (dATP), and deoxyguanosine triphosphate (dGTP) is highly dependent on the activity of ribonucleotide reductase (RNR, Fig. S1), which catalyzes the rate-limiting step in dNTP synthesis and is a well-recognized target for cancer therapy20,21.